Business:
Small Molecules acting to degrade proteins
Drug notes:
KT-413 Clin1 oncology; KT-333 Clin1 multiple cancers; KT-253 Clin0 multiple cancers; 5 undisclosed programs RD autoimmune & fibrotic diseases, immune-inflammatory diseases, oncology
About:
Kymera Therapeutics is developing novel protein degrader therapeutics to treat disease. Cells possess various ways to selectively degrade proteins. Kymera is harnessing these natural processes to selectively degrade disease causing proteins to remove them from the body. To identify effective methods, Kymera is using their proprietary targeted protein degradation platform, Pegasus, which enables the design of highly selective, heterobifunctional small molecule protein degraders. Pegasus works by combining E3 Ligase whole-body expression levels and binders with quantitative system pharmacology. Kymera’s investigational drugs are in development to treat a broad range of immune-inflammatory diseases, hematologic malignancies and solid tumors.
Senior Director, Clinical Operations Watertown, MA|4 days ago
Scientist, Protein Sciences and Lead Discovery (Co... Watertown, MA|5 days ago
Vice President or Senior Vice President, Clinical ... Watertown, MA|7 days ago
Scientist, Targeted Proteomics Watertown, MA|14 days ago
Associate Director or Director, Clinical Scientist... Watertown, MA|15 days ago
Director, Immunology Translational Medicine Watertown, MA|18 days ago
Associate Director, Trial Optimization Lead Watertown, MA|34 days ago
Senior Director, Biostatistics Watertown, MA|61 days ago
Associate Director or Director, Bioanalytical Watertown, MA|62 days ago
Vice President, Safety and Pharmacovigilance Watertown, MA|70 days ago
Director, People Partner Watertown, MA|74 days ago
Principal Scientist or Associate Director, Preclin... Watertown, MA|85 days ago
Director, Research and Development (R&D) Quality Watertown, MA|100+ days ago